Chinese API maker gets stern FDA warning over cross-contamination

Chinese API maker Sichuan Pharmaceutical finds itself on the stinger end of a warning letter just posted to the FDA website. The warning follows two attempts by the drugmaker after a June 2010 inspection to convince the agency it has its previous cross-contamination shortcoming back up to par.

It hasn't achieved that goal. And the FDA appears to imply that some serious consequences are now on the table. "In your response to this letter include your plans for decontamination, renovation, and reactivation (if appropriate) of your facility including the decontamination agent, decontamination plans, analytical methodology for environmental and product testing, and the data obtained to support the effectiveness of the decontamination plan," the letter says.

Inspectors saw the possibility of cross-contamination between adjacent workshops that produced different APIs. The agency also noted that the company lacked an adequate monitoring program.

The drugmaker had sent remediation responses to the FDA following the receipt of the Form 483 inspection report from the inspections in August and December. But they did not satisfy the FDA.

"Your firm has failed to conduct adequate assessment of the cross-contamination risks," the letter says.

- here's Warning Letter 320-11-019

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.